EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives

Sung-Hyun Kim, Sumin Yang, Jeehye Jung, Jeonghyeon Choi, Mingon Kang, Jae-Yeol Joo iD

Advanced Science · 2025

DOI: 10.1002/advs.202413786 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Science, 2025. Verfasst von Sung-Hyun Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do, 15588, Republic of Korea. Hauptthemen laut MEDLINE: Hallucinogens, Mental Disorders, Deep Learning. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 360 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, ICT and Future Planning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mental disorders are a representative type of brain disorder, including anxiety, major depressive depression (MDD), and autism spectrum disorder (ASD), that are caused by multiple etiologies, including genetic heterogeneity, epigenetic dysregulation, and aberrant morphological and biochemical conditions. Psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have been renewed as fascinating treatment options and have gradually demonstrated potential therapeutic effects in mental disorders. However, the multifaceted conditions of psychiatric disorders resulting from individuality, complex genetic interplay, and intricate neural circuits impact the systemic pharmacology of psychedelics, which disturbs the integration of mechanisms that may result in dissimilar medicinal efficiency. The precise prescription of psychedelic drugs remains unclear, and advanced approaches are needed to optimize drug development. Here, recent studies demonstrating the diverse pharmacological effects of psychedelics in mental disorders are reviewed, and emerging perspectives on structural function, the microbiota‐gut‐brain axis, and the transcriptome are discussed. Moreover, the applicability of deep learning is highlighted for the development of drugs on the basis of big data. These approaches may provide insight into pharmacological mechanisms and interindividual factors to enhance drug discovery and development for advanced precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensMental DisordersDeep LearningHumansPsilocybinLysergic Acid Diethylamide

Stichwörter der Autor:innen

artificial intelligencedeep learningdrug developmentmental disorderspsychedelic drugstranscriptome

Substanzen

HallucinogensPsilocybinLysergic Acid Diethylamide

Autor:innen und Institutionen

  • Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do, 15588, Republic of Korea.
  • Department of Computer Science, University of Nevada, Las Vegas, NV, 89154, USA.

ORCID-Profile: Jae-Yeol Joo

Förderung

  • Ministry of Science, ICT and Future Planning

Zitieren

APA

Kim, S. H., Yang, S., Jung, J., Choi, J., Kang, M., & Joo, J. Y. (2025). Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives. Advanced Science. https://doi.org/10.1002/advs.202413786

Vancouver

Kim SH, Yang S, Jung J, Choi J, Kang M, Joo JY. Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives. Advanced Science. 2025. doi:10.1002/advs.202413786

BibTeX
@article{Kim2025,
  author = {Kim, Sung-Hyun and Yang, Sumin and Jung, Jeehye and Choi, Jeonghyeon and Kang, Mingon and Joo, Jae-Yeol},
  title = {Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202413786}
}
Kostenlos starten →